<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00711542</url>
  </required_header>
  <id_info>
    <org_study_id>2007-08-16 REPAIR-ACS</org_study_id>
    <nct_id>NCT00711542</nct_id>
  </id_info>
  <brief_title>Effects of Intracoronary Progenitor Cell Therapy on Coronary Flow Reserve After Acute MI</brief_title>
  <acronym>REPAIR-ACS</acronym>
  <official_title>Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Coronary Syndrome: REPAIR - ACS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary flow reserve is an important measure of the integrity of the coronary
      microcirculation. Moreover, impaired coronary flow reserve is a predictor of future
      cardiovascular events and poor prognosis in patients after acute myocardial infarction.

      After acute myocardial infarction, coronary flow reserve remains significantly reduced. A
      previous randomized, double-blind Placebo-controlled trial (REPAIR-AMI) demonstrated complete
      normalization of coronary flow reserve after intracoronary application of autologous bone
      marrow-derived progenitor cells (but no effect in the placebo group) in patients with ST
      segment elevation myocardial infarction. The current study is planned to extend these
      findings to patients with Non-ST segment elevation myocardial infarction, since these
      patients have an equally reduced outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Improvement of neovascularization is a key mechanism of functional improvement of
      intracoronary application of progenitor cells after acute myocardial infarction. Since
      capillary density cannot be assessed histological in patients, measurement of coronary flow
      reserve is an exact means for estimating capillary density and assessing coronary
      microvascular function. With the help of an intracoronary Doppler Wire, coronary hemodynamics
      can be assessed at baseline and, for example, adenosin-induced maximal vasodilation.
      Calculation of the minimal vascular resistance indices allows to estimate the cross-sectional
      area, reflecting capillary density, and, in comparison with the time of the acute myocardial
      infarction, estimation of improved neovascularization at a later timepoint.

      In order to improve neovascularization, which may then be associated with improved left
      ventricular contractility, we initiated the current trial.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of coronary flow reserve in the infarct vessel</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of relative coronary flow reserve</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of global and regional left ventricular ejection fraction</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (death, MI, rehospitalization for heart failure, revascularization)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (death, MI, rehospitalization for heart failure, revascularization)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intracoronary infusion of autologous bone marrow-derived progenitor cells after NSTEMI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intracoronary infusion of Placebo after NSTEMI</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous bone marrow-derived progenitor cells</intervention_name>
    <description>intracoronary infusion of autologous bone marrow-derived progenitor cells isolated from 50 ml bone marrow aspirate</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo medium</intervention_name>
    <description>intracoronary infusion of placebo medium</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with acute coronary syndrome (ST-depression in at least 2 leads &gt; 0,1 mV), or
        T-wave inversion, with or without elevated myocardial biomarkers (Troponin T oder I),
        together with typical clinical presentation), treated as follows:

          -  Acute percutaneous revascularization with stent implantation within 48 hours after
             symptom onset.

          -  Successful acute PCI (residual stenosis &lt; 30%, TIMI flow &gt; 2).

          -  Hemodynamic stability

          -  Age 18 - 80 years

          -  Written informed consent

          -  Active contraception in women of childbearing age

        Exclusion Criteria:

          -  Patients with STEMI (ST elevation in 2 leads above 0,2 mV in lead V1, V2 oder V3 or
             above 0,1 mV in the other leads)

          -  Necessity of additional PCI in non-infarct vessel at the time of study therapy
             (multi-vessel PCI in the acute event is possible)

          -  Heart failure (LVEF ≤ 30 %).

          -  Arteriovenous malformation or aneurysms

          -  Active infection (C-reactive protein &gt; 10 mg/dl), or fever, or diarrhoea within the
             last 4 weeks

          -  Chronic inflammatory disease

          -  HIV infection or active hepatitis

          -  Neoplastic disease without documented complete remission within the last 5 years

          -  Recent stroke within the last 3 months

          -  Impaired kidney function (creatinin &gt; 2,5 mg/dl) at the time of treatment

          -  Significant liver disease (GOT &gt; 2x upper normal value or spontaneous INR &gt; 1,5.

          -  Hematopoetic disease (anaemia with Hb&lt; 8.5 mg/dl; thrombocytopenia &lt; 100.000/µl;
             splenomegaly

          -  Known allergies to Clopidogrel, Heparin or Abciximab

          -  History of bleeding disorder

          -  GI bleeding within the last 3 months

          -  Major surgery or trauma within the last 2 months

          -  Uncontrolled hypertension

          -  Pregnancy

          -  Mental disability

          -  Previous progenitor cell therapy

          -  Participation in a different clinical trial within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas M Zeiher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Med. Klinik III; Kardiologie</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig / Herzzentrum</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kardiologie-uni-frankfurt.de/</url>
    <description>homepage cardiology university frankfurt</description>
  </link>
  <reference>
    <citation>Erbs S, Linke A, Schächinger V, Assmus B, Thiele H, Diederich KW, Hoffmann C, Dimmeler S, Tonn T, Hambrecht R, Zeiher AM, Schuler G. Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. Circulation. 2007 Jul 24;116(4):366-74. Epub 2007 Jul 9.</citation>
    <PMID>17620510</PMID>
  </reference>
  <reference>
    <citation>Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Werner N, Haase J, Neuzner J, Germing A, Mark B, Assmus B, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI Investigators. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006 Dec;27(23):2775-83. Epub 2006 Nov 10.</citation>
    <PMID>17098754</PMID>
  </reference>
  <reference>
    <citation>Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006 Sep 21;355(12):1210-21.</citation>
    <PMID>16990384</PMID>
  </reference>
  <reference>
    <citation>Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):208-16. Epub 2007 Oct 19. Review.</citation>
    <PMID>17951319</PMID>
  </reference>
  <reference>
    <citation>Schächinger V, Assmus B, Honold J, Lehmann R, Hofmann WK, Martin H, Dimmeler S, Zeiher AM. Normalization of coronary blood flow in the infarct-related artery after intracoronary progenitor cell therapy: intracoronary Doppler substudy of the TOPCARE-AMI trial. Clin Res Cardiol. 2006 Jan;95(1):13-22.</citation>
    <PMID>16598441</PMID>
  </reference>
  <reference>
    <citation>Schächinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, Dimmeler S, Zeiher AM. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol. 2004 Oct 19;44(8):1690-9.</citation>
    <PMID>15489105</PMID>
  </reference>
  <reference>
    <citation>Assmus B, Schächinger V, Teupe C, Britten M, Lehmann R, Döbert N, Grünwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002 Dec 10;106(24):3009-17.</citation>
    <PMID>12473544</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2008</study_first_submitted>
  <study_first_submitted_qc>July 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2008</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>A. M. Zeiher</investigator_full_name>
    <investigator_title>Prof. Dr. Andreas M. Zeiher</investigator_title>
  </responsible_party>
  <keyword>intracoronary progenitor cell therapy</keyword>
  <keyword>NSTEMI</keyword>
  <keyword>coronary flow reserve</keyword>
  <keyword>randomized doubleblind Placebo-controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

